Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, has announced the CADScor System is now being utilized as a diagnostic aid for symptomatic patients suspected of coronary artery disease (CAD) by Saving Grace Concierge in the Oklahoma City and Tulsa metro areas.

Saving Grace offers unique pediatric and adult urgent and primary care services in the privacy of a patient's home. Providers can assess, diagnose, and treat patients, offering comprehensive and compassionate healthcare with the goal of improving quality of life and promoting overall wellness.

"Preventative care is a cornerstone of our practice," stated Grace Mitchell, CNP, founder of Saving Grace Concierge. "We take a personalized approach to address each patient's unique needs, considering family history, lifestyle factors, diagnostic and lab testing results to develop tailored treatment strategies. By integrating the CADScor System into our diagnostic workflow, we gain an objective measure to rule out significant coronary artery disease (CAD) at point of care. This allows us to make immediate decisions, streamlining care and avoiding additional time, testing and costs to our patients. Overall, it enhances the effectiveness of our patient care."

"We are thrilled to see the CADScor System being incorporated into this novel in-home healthcare model," said Aamir Mahmood, President & CEO of Acarix. "The US healthcare system is currently facing overcrowded emergency departments and physician shortages, which are affecting the quality of care patients receive. By partnering with innovators like Saving Grace Concierge, the CADScor System can be utilized early in the diagnostic pathway. This allows for proper risk stratification of patients, enhancing their quality of care and reducing unnecessary testing and hospital visits."

For more information contact:
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com 

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Acarix Secures Multi-Unit Order from In-Home Concierge Practice

© Modular Finance, source Nordic Press Releases